Skarga na jednostronne informacje MZ w sprawie szczepienia przeciwko Sars-Cov-2

List otwarty

Do Ministra Zdrowia

Szanowni Państwo. Mam wrażenie braku bezstronności w sprawie kampanii szczepień ochronnych w sprawie Sars-Cov-2. Istnieje ogromna różnica między informacjami jakie Państwo przekazują a informacjami z prasy medycznej:

"

"SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro"
(...)
Our findings reveal a potential molecular mechanism by which the spike protein might impede adaptive immunity and underscore the potential side effects of full-length spike-based vaccines.(...)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538446/

"Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines"
(...)
Here, we report, besides generation of neutralizing antibodies, consistent alterations in hemoglobin A1c, serum sodium and potassium levels, coagulation profiles, and renal functions in healthy volunteers after vaccination with an inactivated SARS-CoV-2 vaccine. Similar changes had also been reported in COVID-19 patients, suggesting that vaccination mimicked an infection. (...)
https://pubmed.ncbi.nlm.nih.gov/34697287/

"Covid-19: Researcher blows the whistle on data integrity issues in Pfizer's vaccine trial"
(...)
A regional director who was employed at the research organisation Ventavia Research Group has told The BMJ that the company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer's pivotal phase III trial. Staff who conducted quality control checks were overwhelmed by the volume of problems they were finding(...)
https://www.bmj.com/content/375/bmj.n2635.full

"Increases in COVID-19 are unrelated to levels of vaccination across 68 countries and 2947 counties in the United States"
(...)
For instance, in a report released from the Ministry of Health in Israel, the effectiveness of 2 doses of the BNT162b2 (Pfizer-BioNTech) vaccine against preventing COVID-19 infection was reported to be 39% [6], substantially lower than the trial efficacy of 96% [7]. It is also emerging that immunity derived from the Pfizer-BioNTech vaccine may not be as strong as immunity acquired through recovery from the COVID-19 virus [8].(...)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481107/

Proszę o zmianę polityki informacyjnej bo mam wrażenie że doszło do konfliktu interesów gospodarczych. Dziwią zwłaszcza Państwa odpowiedzi na zarzuty fałszerstwa badań naukowych. 

Z wyrazami szacunku

Adam Fularz

Polish News Agency

Dolina Zielona 24a Zielona Góra

--
-------
Merkuriusz Polski
Polish News Agency polishnews.pl